Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus skin drug trial halted early – only 8 volunteers joined

NCT ID NCT05879718

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tested an experimental drug called PF-06823859 for adults with lupus that affects the skin. The goal was to see if the drug could reduce skin inflammation and improve symptoms. The trial was stopped early and only enrolled 8 people instead of the planned 48, so results are very limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

8 people

The number who actually took part.

Started

Jul 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a histologically confirmed active CLE or SLE with cutaneous manifestations in the form of subacute cutaneous lupus erythematosus or/and discoid/chronic cutaneous lupus erythematosus at least 3 months and CLASI-A at least 8 or higher. * Participant has adequate intravenous infusion access per investigator's judgement * Willing to comply with study procedures including skin punch biopsies procedures. * Weight is greater than 40 kg and less than 130 kg. Exclusion Criteria: * Skin disorders other than CLE or SLE. * Active, severe lupus nephritis requiring treatment with cytotoxic agents or high-dose steroids. * Active severe central nervous system lupus requiring therapeutic intervention within 60 days of baseline. * Cancer or a history of cancer within 5 years of screening except adequately resected basal or squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix. * Known history of a major cardiovascular or cerebrovascular event within 24 months, pulmonary arterial hypertension, pulmonary embolism within 6 months of screening. * Have any autoimmune or inflammatory disease that would interfere with interpretation of test results or clinical assessments. * History of disseminated herpes zoster/simplex or recurrent herpes zoster. * Serious infection within 60 days of baseline or an active infection treated with oral antibiotics within 14 days of baseline. * Have evidence of active or latent infection of hepatitis B or C, known history of human immunodeficient virus (HIV) infection, or infected with Mycobacterium TB (active or latent TB) * Laboratory abnormalities that meet exclusion criteria at the Screening visit. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus erythematosus, cutaneous are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus erythematosus, cutaneous Lupus erythematosus, systemic

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • DermEffects

    London, Ontario, N6H 5L5, Canada

  • Dermatological and Venereological Hospital Andreas Syggros

    Athens, 161 21, Greece

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology on Bloor - Research Toronto

    Toronto, Ontario, M4W 2N4, Canada

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, 41013, Spain

  • Ionos Dragoumi 5 Kaisariani

    Kaisarianí, Attikí, 16121, Greece

  • Mayo Clinic Hospital

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic in Arizona - Scottsdale

    Scottsdale, Arizona, 85259, United States

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama, 35233, United States

  • The University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • The University of Kansas Hospital

    Kansas City, Kansas, 66160, United States

  • University General Hospital "ATTIKON" - General Hospital of West Attica "H AGIA VARVARA"

    Chaïdári, Attikí, 124 62, Greece

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama, 35233, United States

  • University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama, 35233, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • Whitby Health Centre

    Whitby, Ontario, L1P 0p9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.